Ocular hypotensive lipids
US6395787B1 · kind B1 · utility
26Cited by
6References
34Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 8, 2000 |
| Grant date | May 28, 2002 |
| Priority date | — |
| Expiry date | Feb 8, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C405/0041
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds of Formula 1, where the symbols are as defined in the specification, are useful as ocular hypotensive agents but do not exert their activity through the FP prostaglandin receptor. In particular the compound PGF2&agr; 1-ethanolamide, having the formula was discovered to be present in mammalian tissue as a naturally occurring substance, was synthesized in a substantially pure form and was found to be effective for lowering intraocular pressure in the mammalian eye, but not acting through the FP receptor through which many ocular hypotensive prostaglandins act.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.